Impax's announcement that it completed its acquisition of Tower Holdings, including Amedra Pharmaceuticals, on 10 March 2015; the branded asset named is the Albenza franchise, and mebendazole is not mentioned.
The privately-held Companies acquired by Impax specialize in the development, manufacture and commercialization of complex generic and branded pharmaceutical products. This profitable and growing portfolio consists of four branded products, including the branded Albenza(R) franchise, Adrenaclick(R) and the related authorized generic, ten complementary commercialized generic products
Impax's announcement that it completed its acquisition of Tower Holdings, including Amedra Pharmaceuticals, on 10 March 2015; the branded asset named is the Albenza franchise, and mebendazole is not mentioned. Company press release (LINK). Deal value $700 million in cash, announced 9 October 2014, closed 10 March 2015. Named branded products: Albenza, Adrenaclick, Dexedrine, Daraprim. Amedra Pharmaceuticals LLC is described as a Tower Holdings subsidiary based in Horsham, PA. Bearing is CONTRADICTS as to C5's pairing of Amedra with mebendazole: the record shows Amedra's branded anthelmintic was albendazole (Albenza). Mebendazole reached Impax separately, via the Teva ANDA purchase recorded in MBA-24. Context: the deal was $700 million and Albenza is albendazole; this corrects the grouping of Amedra as a mebendazole holder.
